Astellas Pharma Inc (4503.T)

4503.T on Tokyo Stock Exchange

1,620JPY
5:06am BST
Price Change (% chg)

¥24 (+1.47%)
Prev Close
¥1,596
Open
¥1,586
Day's High
¥1,623
Day's Low
¥1,586
Volume
5,166,300
Avg. Vol
5,624,954
52-wk High
¥1,630
52-wk Low
¥945

4503.T

Chart for 4503.T

About

Astellas Pharma Inc. is a Japan-based company mainly engaged in the pharmaceutical business. The Company is involved in the manufacture and sale of pharmaceutical products in Japan, the United States, Europe, China, Korea and Taiwan, through its subsidiaries. Its main products include immunosuppressive drug Prograf, overactive... (more)

Overall

Beta: 0.64
Market Cap (Mil.): ¥3,606,678.00
Shares Outstanding (Mil.): 2,259.82
Dividend: 14.00
Yield (%): 1.69

Financials

  4503.T Industry Sector
P/E (TTM): 34.15 33.02 33.86
EPS (TTM): 46.73 -- --
ROI: 8.62 18.15 17.39
ROE: 9.02 18.85 18.25
Search Stocks

U.S. FDA approves expanded use of Medivation prostate cancer drug

- U.S. health regulators approved the use of Medivation Inc's and Astellas Pharma Inc's advanced prostate cancer drug Xtandi in men who have not yet received chemotherapy, the companies said on Wednesday, significantly expanding the potential patient population for the oral medicine.

10 Sep 2014

UPDATE 1-U.S. FDA approves expanded use of Medivation prostate cancer drug

Sept 10 - U.S. health regulators approved the use of Medivation Inc's and Astellas Pharma Inc's advanced prostate cancer drug Xtandi in men who have not yet received chemotherapy, the companies said on Wednesday, significantly expanding the potential patient population for the oral medicine.

10 Sep 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Reuters Investment Profile
£10.00
Provider: MarketLine (a Datamonitor Company)
£114.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks